Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry

Abstract Aims Heart failure (HF) is a risk factor for major adverse events in atrial fibrillation (AF). Whether this risk persists on non-vitamin K antagonist oral anticoagulants (NOACs) and varies according to left ventricular ejection fraction (LVEF) is debated. Methods and results We investigated...

Full description

Saved in:
Bibliographic Details
Published in:Europace (London, England) England), 2023-08, Vol.25 (9)
Main Authors: Schnabel, Renate B, Ameri, Pietro, Siller-Matula, Jolanta M, Diemberger, Igor, Gwechenberger, Marianne, Pecen, Ladislav, Manu, Marius Constantin, Souza, José, De Caterina, Raffaele, Kirchhof, Paulus
Format: Article
Language:English
Subjects:
Administration, Oral
Anticoagulants - adverse effects
Atrial Fibrillation - complications
Atrial Fibrillation - diagnosis
Atrial Fibrillation - drug therapy
Brain Ischemia
Clinical Research
Embolism
Heart Failure - diagnosis
Heart Failure - epidemiology
Hemorrhage - chemically induced
Humans
Ischemic Attack, Transient - diagnosis
Ischemic Attack, Transient - epidemiology
Ischemic Attack, Transient - prevention & control
Ischemic Stroke
Male
Prospective Studies
Registries
Stroke - diagnosis
Stroke - epidemiology
Stroke - etiology
Stroke Volume - physiology
Ventricular Function, Left
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aims Heart failure (HF) is a risk factor for major adverse events in atrial fibrillation (AF). Whether this risk persists on non-vitamin K antagonist oral anticoagulants (NOACs) and varies according to left ventricular ejection fraction (LVEF) is debated. Methods and results We investigated the relation of HF in the ETNA-AF-Europe registry, a prospective, multicentre, observational study with an overall 4-year follow-up of edoxaban-treated AF patients. We report 2-year follow-up for ischaemic stroke/transient ischaemic attack (TIA)/systemic embolic events (SEE), major bleeding, and mortality. Of the 13 133 patients, 1854 (14.1%) had HF. Left ventricular ejection fraction was available for 82.4% of HF patients and was
ISSN:1099-5129
1532-2092
1532-2092
DOI:10.1093/europace/euad280